FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.871,57 +325,51 (+0,56%)
Krystal Biotech Inc (4KB.BE)
| Chiusura precedente | 150,60 |
| Aperto | 150,10 |
| Denaro | 148,60 x 0 |
| Lettera | 150,50 x 0 |
| Min-Max giorno | 148,05 - 152,30 |
| Intervallo di 52 settimane | 75,50 - 168,90 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireKrystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Chardan 7th Annual Genetic Medicines Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conferenc
- GlobeNewswire
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug Application (IND) for KB408 for the treatment of alpha-1 antitrypsin deficiency (A
- GlobeNewswire
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the c
